Aligos therapeutics presents clinical data for its nash program and nonclinical data for its chronic hepatitis b portfolio at aasld's the liver meeting® 2022

Alg-055009, a thr-Β agonist drug candidate in development as a treatment for nash, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia
ALGS Ratings Summary
ALGS Quant Ranking